Annovis Bio Inc. (NYSE: ANVS) reported its first-quarter 2026 business and financial results, highlighting continued advancement of its clinical-stage neurodegenerative disease programs. The company announced that its pivotal Phase 3 Alzheimer’s disease trial has reached 85% enrollment, and enrollment to new participants has been closed after achieving sufficient screening levels to meet enrollment goals. This milestone brings Annovis closer to potential regulatory submission for its lead drug candidate, buntanetap.
In addition to the Alzheimer’s program, Annovis reported progress in its Parkinson’s disease open-label extension study, which has reached 40% enrollment. The company also outlined new biomarker initiatives and AI-powered digital monitoring as it continues advancing buntanetap toward potential regulatory submission. Buntanetap, an investigational once-daily oral therapy, inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The significance of these developments lies in the potential impact on millions of patients suffering from Alzheimer’s and Parkinson’s diseases. Alzheimer’s disease affects an estimated 6.5 million Americans, while Parkinson’s impacts nearly 1 million. Current treatments primarily manage symptoms rather than addressing root causes. If buntanetap proves effective, it could represent a major shift in how neurodegenerative diseases are treated, potentially slowing or halting progression rather than just alleviating symptoms.
For the industry, Annovis’s progress may signal a new era in neurodegenerative drug development. The company’s approach of targeting multiple neurotoxic proteins simultaneously could offer advantages over single-target therapies. The use of AI-powered digital monitoring also reflects a growing trend in clinical trials to leverage technology for more precise data collection and analysis.
Investors and stakeholders should note that the closure of enrollment in the Phase 3 Alzheimer’s trial suggests the company is on track to complete the study and potentially file for regulatory approval. The Parkinson’s open-label extension study provides additional safety and efficacy data that could support broader indications for buntanetap. Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
For more information, visit the company’s newsroom at https://ibn.fm/ANVS. The full press release is available at https://ibn.fm/M77X4.
